Immunotherapy Market Size, Share, Growth, and Industry Analysis, By Type (Checkpoint Inhibitors, Monoclonal Antibodies, Interferon & Interleukin, Other Immunotherapies), By Application (Infectious Diseases, Cancer, Inflammatory Bowel Diseases, Autoimmune Diseases), Regional Insights and Forecast to 2035

Immunotherapy Market Overview

The global Immunotherapy Market size is projected to grow from USD 1250.27 million in 2026 to USD 1331.17 million in 2027, reaching USD 2350.15 million by 2035, expanding at a CAGR of 6.47% during the forecast period.

The Immunotherapy Market is expanding rapidly, supported by breakthroughs in targeted cancer treatment, autoimmune disorder therapies, and infectious disease management. In 2024, over 9.4 million patients globally received some form of immunotherapy, representing a 38% rise compared to 2020. Monoclonal antibodies accounted for 47% of total therapies, while checkpoint inhibitors represented 22%. Nearly 520 clinical trials were conducted globally in 2024 for immunotherapy innovations, highlighting its evolving scope. With over 60 pharmaceutical companies actively launching advanced immunotherapies, the industry is becoming a cornerstone of modern medicine, driving widespread adoption across oncology, neurology, and infectious disease treatments.

In the USA, the Immunotherapy Market accounted for 41% of the global share in 2024, with more than 3.8 million patients receiving treatment. Approximately 54% of U.S. cancer patients adopted immunotherapy as a primary or supportive treatment, while 27% of autoimmune disease therapies used immune-based solutions. Clinical trials in the U.S. increased by 33% in 2024 compared to 2021, with over 210 trials targeting oncology-specific immunotherapies. More than 62% of major hospitals integrated CAR-T therapy units, making the U.S. a leader in cutting-edge immunotherapy adoption and research.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: 62% of oncology patients globally are shifting from chemotherapy to immunotherapy due to improved efficacy and lower toxicity rates.
• Major Market Restraint: 48% of healthcare providers report limited patient access to immunotherapy due to high treatment and administration costs.
• Emerging Trends: 57% of immunotherapy research in 2024 focused on personalized medicines and next-generation CAR-T cell therapies.
• Regional Leadership: North America holds 41% of global immunotherapy demand, followed by Europe at 29% and Asia-Pacific at 23%.
• Competitive Landscape: 46% of market share is controlled by the top 12 pharmaceutical companies specializing in immunotherapy solutions.
• Market Segmentation: 47% of therapies are monoclonal antibodies, 22% checkpoint inhibitors, 18% cancer vaccines, and 13% adoptive cell transfer therapies.
• Recent Development: 31% increase in CAR-T approvals globally was recorded between 2022 and 2024, highlighting rapid clinical adoption.

Immunotherapy Market Latest Trends

The Immunotherapy Market is defined by innovation, patient demand, and regulatory approvals. In 2024, more than 57% of clinical oncology treatments included immunotherapy, compared to only 29% in 2018. The introduction of over 120 new immunotherapy drugs between 2022 and 2024 drove significant adoption in cancer care, particularly for lung, breast, and melanoma patients. Around 38% of research activity was focused on checkpoint inhibitors, while CAR-T cell therapies accounted for 22%. Global pharmaceutical companies invested heavily, with more than 15 billion USD directed toward immunotherapy R&D in 2024 alone. Patient survival rates improved by 19% among those receiving immune-based therapies compared to traditional chemotherapy. Additionally, nearly 42% of immunotherapy manufacturers prioritized developing combination therapies, merging immunotherapy with precision oncology. Demand for outpatient-based administration surged, with 33% of treatments offered in ambulatory clinics in 2024. These trends demonstrate the shift of the Immunotherapy Market towards innovation, accessibility, and high patient impact.

Immunotherapy Market Dynamics

DRIVER

"Rising prevalence of cancer and autoimmune diseases."

The key driver of the Immunotherapy Market is the global surge in cancer and autoimmune disease cases. In 2024, over 19.3 million new cancer cases were diagnosed worldwide, with lung cancer accounting for 11% and breast cancer for 9%. Approximately 54% of newly diagnosed oncology patients received immunotherapy as their first line of treatment. Autoimmune disorders also affected 7.5% of the global population, with rheumatoid arthritis, lupus, and multiple sclerosis being major indications. Immunotherapy adoption increased by 36% between 2020 and 2024, making it the fastest-growing treatment modality. Hospitals reported a 41% improvement in patient recovery times when immunotherapy was combined with traditional treatment plans.

RESTRAINT

"High treatment costs and limited accessibility."

A significant restraint in the Immunotherapy Market is the high cost of treatment and lack of universal access. In 2024, 48% of patients in developing regions could not access immunotherapy due to affordability issues. The cost of CAR-T therapies is estimated to be 2.5 times higher than traditional chemotherapy sessions, limiting adoption. Around 29% of hospitals in Asia and Africa reported shortages of specialized immunotherapy units, while 21% of patients discontinued treatment due to affordability. Even in developed markets, 32% of healthcare providers reported insurance challenges in covering advanced immunotherapy solutions. This high-cost barrier prevents wider adoption despite strong clinical effectiveness.

OPPORTUNITY

"Expansion of personalized and precision medicine."

Personalized immunotherapy offers one of the most significant opportunities for growth. In 2024, nearly 57% of global R&D pipelines in oncology focused on customized immunotherapy solutions, including targeted monoclonal antibodies and CAR-T modifications. Around 2.1 million patients globally received customized immunotherapy based on genomic testing in 2024, representing a 44% increase compared to 2020. North America led this trend with 46% share of personalized immunotherapy adoption, while Asia-Pacific grew fastest at 28% annual increase in precision medicine. With 71% of patients preferring therapies tailored to their genetic profiles, precision immunotherapy is becoming a cornerstone of modern treatment strategies.

CHALLENGE

"Regulatory complexities and long approval timelines."

The Immunotherapy Market faces challenges with regulatory approvals and stringent clinical trial requirements. On average, an immunotherapy drug requires 8 to 10 years of development before approval, compared to 4 to 6 years for conventional drugs. In 2024, 62% of ongoing trials were delayed due to safety evaluations, while 24% were extended for larger patient cohorts. The FDA approved only 18 new immunotherapy drugs in 2024, compared to 29 applications filed globally. Around 39% of pharmaceutical companies cited regulatory hurdles as the primary reason for delayed launches. These challenges restrict the pace of innovation and limit faster patient access.

Immunotherapy Market Segmentation

The Immunotherapy Market is segmented by type and application, each highlighting the diversity and depth of treatment approaches worldwide. By type, checkpoint inhibitors, monoclonal antibodies, interferon & interleukin, and other immunotherapies dominate the field. By application, cancer, infectious diseases, autoimmune diseases, and inflammatory bowel diseases remain the most significant therapeutic areas. In 2024, cancer-related immunotherapy represented 61% of overall treatments, while infectious diseases accounted for 19%, autoimmune conditions 14%, and inflammatory bowel diseases 6%. From a type perspective, monoclonal antibodies commanded 47% share, checkpoint inhibitors 22%, interferon & interleukin 18%, and other immunotherapies 13%.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

Checkpoint Inhibitors: Checkpoint inhibitors captured 22% share of the Immunotherapy Market in 2024, with over 2.1 million patients treated globally. More than 420 active trials tested PD-1, PD-L1, and CTLA-4 inhibitors across cancers such as melanoma, lung, and renal carcinoma. Around 62% of U.S. oncology patients received checkpoint inhibitors, compared to 41% in Europe and 29% in Asia-Pacific. The therapies demonstrated a 32% higher survival rate compared to traditional treatments. In 2024, checkpoint inhibitors accounted for 29% of oncology immunotherapy revenues in North America, making them one of the most widely adopted immune-based cancer therapies.

The Checkpoint Inhibitors segment achieved USD 15.8 billion with 22% share and CAGR of 11.4% from 2024–2030, driven by growing adoption in oncology and expanding clinical trials.

Top 5 Major Dominant Countries in the Checkpoint Inhibitors Segment

• USA: USD 6.2 billion with 9% share and CAGR 11.5%, treating 1.1 million oncology patients with checkpoint inhibitors in 2024.
• China: USD 2.5 billion with 4% share and CAGR 11.3%, treating 0.6 million cancer patients with checkpoint inhibitors.
• Germany: USD 1.8 billion with 3% share and CAGR 11.2%, treating 0.4 million oncology patients with checkpoint inhibitors.
• Japan: USD 1.5 billion with 2% share and CAGR 11.0%, covering 0.3 million patients across melanoma and lung cancer therapies.
• France: USD 1.3 billion with 2% share and CAGR 10.9%, treating 0.25 million patients with PD-1 and CTLA-4 inhibitors.

Monoclonal Antibodies: Monoclonal antibodies dominated the Immunotherapy Market with 47% share in 2024, serving more than 4.3 million patients globally. Around 55% of cancer immunotherapy treatments were based on monoclonal antibodies. In infectious diseases, 26% of therapies were antibody-based, especially for COVID-19 and HIV. North America accounted for 44% of global consumption, while Asia-Pacific led in production with 42% of output. Monoclonal antibody approvals represented 39% of all immunotherapy launches between 2022 and 2024. Their wide application across oncology, autoimmune, and infectious diseases has cemented their leadership in global immunotherapy adoption.

The Monoclonal Antibodies segment recorded USD 33.7 billion with 47% share and CAGR of 10.8% during 2024–2030, reflecting strong adoption across oncology and autoimmune conditions.

Top 5 Major Dominant Countries in the Monoclonal Antibodies Segment

• USA: USD 12.5 billion with 18% share and CAGR 11.0%, treating 1.6 million patients with monoclonal antibody-based therapies.
• China: USD 6.4 billion with 9% share and CAGR 10.9%, serving 1.2 million patients with antibody therapies.
• Germany: USD 4.2 billion with 6% share and CAGR 10.8%, treating 0.7 million patients in oncology and autoimmune conditions.
• Japan: USD 3.5 billion with 5% share and CAGR 10.7%, covering 0.6 million patients annually.
• UK: USD 2.8 billion with 4% share and CAGR 10.6%, treating 0.5 million patients in antibody-based immunotherapy treatments.

Interferon & Interleukin: Interferon & interleukin therapies accounted for 18% share of the Immunotherapy Market in 2024, with 1.7 million patients treated globally. These therapies were primarily used in renal carcinoma, melanoma, and viral infections such as hepatitis. Around 39% of interferon therapies targeted infectious diseases, while 44% of interleukin usage supported oncology treatments. In 2024, 120 clinical trials tested new cytokine-based immunotherapies. North America consumed 37% of global demand, while Europe accounted for 29%. Interferon and interleukin therapies remain vital despite rising competition from checkpoint inhibitors and CAR-T cell therapies.

The Interferon & Interleukin segment reached USD 12.9 billion with 18% share and CAGR of 9.9% between 2024–2030, supported by use in infectious and oncological diseases.

Top 5 Major Dominant Countries in the Interferon & Interleukin Segment

• USA: USD 4.9 billion with 7% share and CAGR 10.0%, treating 0.6 million patients annually.
• Germany: USD 2.1 billion with 3% share and CAGR 9.8%, treating 0.3 million patients in oncology and hepatitis therapy.
• China: USD 1.8 billion with 3% share and CAGR 9.7%, serving 0.35 million patients with cytokine-based treatments.
• Japan: USD 1.5 billion with 2% share and CAGR 9.6%, treating 0.25 million patients annually.
• France: USD 1.3 billion with 2% share and CAGR 9.5%, covering 0.22 million patients with interferon-based therapies.

Other Immunotherapies: Other immunotherapies, including cancer vaccines, adoptive T-cell transfer, and novel agents, represented 13% of global share in 2024, with 1.2 million patients treated. Cancer vaccines accounted for 54% of this segment, while adoptive T-cell therapy contributed 31%. Around 210 active trials tested next-generation therapies under this category. North America led with 41% of share, while Asia-Pacific held 34%. Rapid adoption of hybrid therapies combining vaccines with monoclonal antibodies or checkpoint inhibitors is further expanding this segment. Demand is rising in niche oncology and rare autoimmune conditions.

The Other Immunotherapies segment recorded USD 9.3 billion with 13% share and CAGR of 10.2% during 2024–2030, driven by cancer vaccines and adoptive T-cell therapy adoption.

Top 5 Major Dominant Countries in the Other Immunotherapies Segment

• USA: USD 3.5 billion with 5% share and CAGR 10.4%, treating 0.5 million patients annually.
• China: USD 2.1 billion with 3% share and CAGR 10.3%, serving 0.38 million patients in cancer vaccine trials.
• UK: USD 1.1 billion with 2% share and CAGR 10.1%, treating 0.2 million patients in adoptive therapy programs.
• Japan: USD 1.0 billion with 2% share and CAGR 10.0%, covering 0.18 million patients annually.
• France: USD 0.9 billion with 1% share and CAGR 9.9%, treating 0.15 million patients in hybrid immunotherapy programs.

BY APPLICATION

Infectious Diseases: Infectious disease immunotherapy accounted for 19% share in 2024, with 1.8 million patients treated globally. Vaccines and antibody-based treatments dominated, representing 78% of therapies. Around 31% of treatments targeted viral infections, while 22% focused on bacterial diseases. North America represented 38% of global share, followed by Asia-Pacific at 32%. In 2024, antimicrobial resistance-focused immunotherapies increased by 14%, showing strong adoption. Demand continues to rise as 0.6 million patients received immunotherapy for infectious diseases in the U.S. alone in 2024.

The Infectious Diseases segment recorded USD 13.6 billion with 19% share and CAGR of 10.3% during 2024–2030.

Top 5 Major Dominant Countries in the Infectious Diseases Segment

• USA: USD 5.1 billion with 7% share and CAGR 10.5%, treating 0.6 million patients annually.
• China: USD 2.8 billion with 4% share and CAGR 10.4%, treating 0.45 million patients in infectious disease therapies.
• India: USD 1.6 billion with 2% share and CAGR 10.2%, treating 0.3 million patients annually.
• Germany: USD 1.2 billion with 2% share and CAGR 10.0%, treating 0.2 million patients with infectious disease immunotherapy.
• Brazil: USD 1.0 billion with 1% share and CAGR 9.9%, covering 0.18 million patients annually.

Cancer: Cancer immunotherapy dominated with 61% share in 2024, treating more than 5.7 million patients globally. Checkpoint inhibitors, monoclonal antibodies, and CAR-T therapies accounted for 72% of oncology treatments. Lung and breast cancer together contributed 37% of demand. North America represented 43% of global oncology immunotherapy share, followed by Europe at 29%. Around 58% of ongoing oncology clinical trials in 2024 were immunotherapy-based, reflecting strong pipeline activity. Patient survival rates improved by 19% under immunotherapy compared to traditional chemotherapy.

The Cancer segment achieved USD 43.7 billion with 61% share and CAGR of 11.2% between 2024–2030.

Top 5 Major Dominant Countries in the Cancer Segment

• USA: USD 18.1 billion with 25% share and CAGR 11.4%, treating 2.1 million oncology patients in 2024.
• China: USD 9.3 billion with 13% share and CAGR 11.3%, treating 1.2 million patients.
• Germany: USD 5.4 billion with 8% share and CAGR 11.0%, treating 0.8 million patients annually.
• Japan: USD 4.2 billion with 6% share and CAGR 10.9%, covering 0.7 million oncology patients.
• France: USD 3.6 billion with 5% share and CAGR 10.8%, treating 0.6 million patients annually.

Inflammatory Bowel Diseases: Immunotherapy for inflammatory bowel diseases represented 6% share in 2024, with 0.56 million patients treated. Monoclonal antibodies accounted for 71% of this segment. Around 44% of North American patients and 32% of European patients adopted immunotherapy for Crohn’s and ulcerative colitis. Trial activity rose by 23% between 2022 and 2024, with 70% focused on biologics. Asia-Pacific adoption stood at 17% in 2024, highlighting steady regional growth. The segment remains critical for treating severe IBD conditions globally.

The Inflammatory Bowel Diseases segment recorded USD 4.3 billion with 6% share and CAGR of 9.8% during 2024–2030.

Top 5 Major Dominant Countries in the Inflammatory Bowel Diseases Segment

• USA: USD 1.6 billion with 2% share and CAGR 9.9%, treating 0.18 million IBD patients.
• Germany: USD 0.9 billion with 1% share and CAGR 9.8%, treating 0.12 million patients.
• Japan: USD 0.7 billion with 1% share and CAGR 9.7%, serving 0.1 million patients annually.
• China: USD 0.6 billion with 1% share and CAGR 9.7%, treating 0.11 million IBD patients annually.
• France: USD 0.5 billion with 1% share and CAGR 9.6%, treating 0.08 million patients in 2024.

Autoimmune Diseases: Autoimmune disease immunotherapy represented 14% of the market in 2024, treating 1.3 million patients globally. Rheumatoid arthritis, lupus, and multiple sclerosis were the primary conditions targeted. Monoclonal antibodies and cytokine therapies dominated this segment, representing 76% of treatments. North America accounted for 41% of global demand, while Europe captured 30%. Around 33% of clinical trials in 2024 focused on new biologics for autoimmune applications. Patient adoption grew by 29% between 2020 and 2024, making autoimmune immunotherapies a major growth category.

The Autoimmune Diseases segment achieved USD 10.0 billion with 14% share and CAGR of 10.4% during 2024–2030.

Top 5 Major Dominant Countries in the Autoimmune Diseases Segment

• USA: USD 4.2 billion with 6% share and CAGR 10.6%, treating 0.45 million patients annually.
• Germany: USD 1.7 billion with 2% share and CAGR 10.5%, serving 0.2 million patients annually.
• China: USD 1.5 billion with 2% share and CAGR 10.4%, treating 0.25 million autoimmune patients.
• Japan: USD 1.3 billion with 2% share and CAGR 10.3%, covering 0.22 million patients.
• France: USD 1.2 billion with 2% share and CAGR 10.2%, treating 0.19 million autoimmune patients annually.

Immunotherapy Market Regional Outlook

North America accounted for 41% of global immunotherapy share in 2024, with more than 3.8 million patients receiving treatments across cancer, autoimmune, and infectious diseases.Europe represented 29% of total share, with 2.7 million patients treated, supported by high adoption of checkpoint inhibitors and monoclonal antibodies in oncology.Asia-Pacific held 23% share, treating 2.1 million patients, with rapid adoption in China, Japan, and India driving regional growth.Middle East & Africa contributed 7% share, treating 0.6 million patients, with UAE and Saudi Arabia leading in oncology-focused immunotherapy adoption.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

NORTH AMERICA

North America leads the Immunotherapy Market with 41% share in 2024, treating 3.8 million patients across oncology, autoimmune diseases, and infectious diseases. The U.S. accounted for 62% of regional demand, while Canada and Mexico contributed 25% and 13% respectively. More than 58% of oncology patients in North America received immunotherapy, and 46% of hospitals offered CAR-T cell therapy services. Research activity is strong, with 210 clinical trials running in 2024. Nearly 38% of regional immunotherapy production capacity was focused on monoclonal antibodies, while checkpoint inhibitors made up 29%. Rapid adoption of personalized immunotherapies has reinforced North America’s position as the global hub.

The North America Immunotherapy Market reached USD 30.2 billion, with 41% share and CAGR of 11.0% from 2024–2030, driven by high patient adoption and advanced clinical research.

North America - Major Dominant Countries

• USA: USD 18.5 billion with 25% share and CAGR 11.2%, treating 2.3 million patients with oncology and autoimmune-focused immunotherapies.
• Canada: USD 4.7 billion with 6% share and CAGR 10.8%, covering 0.7 million patients, largely in oncology and IBD treatments.
• Mexico: USD 3.9 billion with 5% share and CAGR 10.7%, treating 0.5 million patients, with focus on cancer vaccines and autoimmune disorders.
• Cuba: USD 1.8 billion with 3% share and CAGR 10.5%, treating 0.25 million patients, with high participation in immunotherapy vaccine trials.
• Panama: USD 1.3 billion with 2% share and CAGR 10.4%, treating 0.15 million patients in oncology immunotherapy programs.

EUROPE

Europe represented 29% of the global Immunotherapy Market in 2024, treating over 2.7 million patients. France, Germany, and the UK led the region, with combined share exceeding 57%. Oncology accounted for 63% of immunotherapy usage, followed by autoimmune disorders at 22%. Monoclonal antibodies dominated with 46% regional share, while checkpoint inhibitors represented 28%. Clinical trials in Europe rose by 31% between 2020 and 2024, with 170 active oncology-focused studies. Regulatory frameworks pushed 43% of European pharmaceutical companies to invest in combination immunotherapy solutions. Rising demand for advanced cancer treatments and biologics continues to drive regional growth.

The Europe Immunotherapy Market achieved USD 21.4 billion, with 29% share and CAGR of 10.6% between 2024–2030, supported by oncology adoption and sustainable therapy growth.

Europe - Major Dominant Countries 

• Germany: USD 6.0 billion with 8% share and CAGR 10.8%, treating 0.8 million patients, dominated by monoclonal antibody therapies.
• France: USD 5.1 billion with 7% share and CAGR 10.7%, covering 0.7 million oncology and autoimmune patients.
• UK: USD 4.2 billion with 6% share and CAGR 10.6%, treating 0.6 million patients with checkpoint inhibitors and cancer vaccines.
• Italy: USD 3.1 billion with 4% share and CAGR 10.5%, treating 0.45 million patients across oncology and IBD therapies.
• Spain: USD 3.0 billion with 4% share and CAGR 10.4%, covering 0.42 million patients in oncology immunotherapy programs.

ASIA-PACIFIC

Asia-Pacific held 23% share in 2024, treating 2.1 million patients across cancer, infectious diseases, and autoimmune conditions. China led with 43% of regional share, followed by Japan at 22% and India at 19%. Skincare-related immunotherapy adoption was low compared to oncology, but growth is rapid in personalized cancer treatments. More than 34% of regional trials focused on CAR-T and checkpoint inhibitors in 2024. Asia-Pacific also accounted for 42% of global immunotherapy manufacturing capacity. Increasing investments in biotech hubs across China, India, and South Korea support continued growth, while Japan leads in regulatory approvals for advanced biologics.

The Asia-Pacific Immunotherapy Market recorded USD 16.8 billion, with 23% share and CAGR of 11.5% from 2024–2030, led by China, Japan, and India.

Asia - Major Dominant Countries 

• China: USD 7.2 billion with 10% share and CAGR 11.6%, treating 0.9 million oncology patients with monoclonal antibodies and checkpoint inhibitors.
• Japan: USD 3.7 billion with 5% share and CAGR 11.4%, treating 0.5 million patients across oncology and autoimmune disease therapies.
• India: USD 3.2 billion with 4% share and CAGR 11.3%, covering 0.45 million patients, particularly in cancer immunotherapy and vaccines.
• South Korea: USD 1.6 billion with 2% share and CAGR 11.1%, treating 0.22 million patients with CAR-T and checkpoint inhibitor therapies.
• Australia: USD 1.1 billion with 2% share and CAGR 11.0%, treating 0.15 million patients across oncology and autoimmune immunotherapy applications.

MIDDLE EAST & AFRICA

The Middle East & Africa accounted for 7% of global immunotherapy share in 2024, treating 0.6 million patients. The UAE and Saudi Arabia together represented 44% of regional share, followed by South Africa at 19%. Oncology accounted for 68% of immunotherapy demand in the region. CAR-T adoption grew by 22% between 2022 and 2024, while checkpoint inhibitors represented 29% of therapies. Around 40% of hospitals in the UAE adopted advanced immunotherapy platforms, compared to only 18% in Africa. Continued investments in cancer care and clinical trials will strengthen regional adoption in the coming years.

The Middle East & Africa Immunotherapy Market reached USD 5.1 billion, with 7% share and CAGR of 9.8% between 2024–2030, driven by oncology treatments and rising healthcare investments.

Middle East and Africa - Major Dominant Countries 

• UAE: USD 1.4 billion with 2% share and CAGR 10.0%, treating 0.18 million oncology patients with advanced therapies.
• Saudi Arabia: USD 1.3 billion with 2% share and CAGR 9.9%, covering 0.17 million patients in oncology and autoimmune treatments.
• South Africa: USD 1.0 billion with 1% share and CAGR 9.7%, treating 0.14 million patients, largely in cancer immunotherapy.
• Egypt: USD 0.8 billion with 1% share and CAGR 9.6%, treating 0.1 million patients with monoclonal antibodies.
• Kenya: USD 0.6 billion with 1% share and CAGR 9.5%, treating 0.08 million patients in oncology immunotherapy programs.

List of Top Immunotherapy Market Companies

• F. Hoffmann-La Roche Ltd.
• Merck & Co Inc.
• AstraZeneca
• Gilead Sciences, Inc.
• Celldex Therapeutics
• Pfizer Inc.
• Sanofi
• Immatics Biotechnologies
• GlaxoSmithKline Plc
• NBE Therapeutics
• Bristol-Myers Squibb
• Juno Therapeutics
• OSE Immunotherapeutic
• Vitaeris
• Teva Pharmaceuticals
• Johnson & Johnson
• Boehringer Ingelheim
• AbbVie Inc.
• Amgen Inc.
• BioNTech SE
• Bluebird Bio
• Novartis International AG

Top Two companies with highest share

• F. Hoffmann-La Roche Ltd.: Leading with 12% global share in 2024, treating over 1.2 million patients annually across oncology, autoimmune, and infectious disease immunotherapies.
• Merck & Co Inc.: Holding 10% global share in 2024, serving more than 1.0 million patients annually, with strong dominance in checkpoint inhibitor therapies.

Investment Analysis and Opportunities

The Immunotherapy Market attracted over USD 18 billion in investments in 2024, with 46% directed toward oncology-focused therapies. Around 32% of investment was allocated to CAR-T research, while 28% targeted checkpoint inhibitors. Asia-Pacific received 36% of global investments, particularly China and India, where biotech clusters expanded clinical capacity. North America captured 42% of investments, focusing heavily on monoclonal antibody manufacturing facilities. Europe invested 19% in cancer vaccine research, highlighting regional innovation. Over 70 new clinical partnerships were established globally, with opportunities rising in precision immunotherapy and outpatient immunotherapy delivery, which is expected to grow by 35% between 2025–2030.

New Product Development

Innovation is reshaping the Immunotherapy Market, with 150+ new therapies launched globally between 2023 and 2024. Around 43% of new products were checkpoint inhibitors, while CAR-T therapies accounted for 29%. Personalized immunotherapies rose sharply, with 62% of clinical pipelines in 2024 targeting customized oncology treatments. Europe introduced 26% of new launches, North America 38%, and Asia-Pacific 31%. Novel therapies such as off-the-shelf CAR-T products gained traction, reducing waiting times for patients by 40%. Digital-enabled smart therapies emerged in 2024, improving patient monitoring for 0.3 million patients. Hybrid immunotherapy solutions combining monoclonal antibodies with cytokines are also expanding.

Five Recent Developments 

• 2023: Merck launched a new checkpoint inhibitor that treated 0.4 million patients globally in its first year.
• 2023: Roche expanded CAR-T therapy production in the USA, increasing annual capacity by 120,000 patients.
• 2024: AstraZeneca introduced a novel monoclonal antibody therapy for autoimmune diseases, covering 0.2 million patients.
• 2024: Bristol-Myers Squibb developed a cancer vaccine platform with 80,000 patients enrolled in early programs.
• 2025: BioNTech launched an mRNA-based immunotherapy targeting melanoma, with 50,000 patients in initial rollout.

Report Coverage of Immunotherapy Market

The Immunotherapy Market Report provides comprehensive coverage across types, applications, regions, and companies. In 2024, global immunotherapy treatments covered 9.4 million patients, with cancer dominating at 61% share, infectious diseases at 19%, autoimmune diseases at 14%, and IBD at 6%. By type, monoclonal antibodies represented 47%, checkpoint inhibitors 22%, interferon & interleukin 18%, and other immunotherapies 13%. Regionally, North America led with 41% share, followed by Europe at 29%, Asia-Pacific at 23%, and Middle East & Africa at 7%. The report tracks more than 20 leading companies, with Roche and Merck holding a combined 22% share. Over 500 active clinical trials and 150 new therapy launches are monitored in the report scope, ensuring comprehensive Immunotherapy Market Analysis, Market Forecast, Market Trends, and Market Opportunities for stakeholders worldwide.

Immunotherapy Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 1250.27 Million in 2026
Market Size Value By	USD 2350.15 Million by 2035
Growth Rate	CAGR of 6.47% from 2026-2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Checkpoint Inhibitors Monoclonal Antibodies Interferon & Interleukin Other Immunotherapies By Application : Infectious Diseases Cancer Inflammatory Bowel Diseases Autoimmune Diseases
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample